Rafferty Asset Management
CRVS icon

Rafferty Asset Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Rafferty Asset Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.22M Sell
81,494
-31,114
-28% -$432K ﹤0.01% 746
2026
Q1 		$1.65M Buy
112,608
+12,884
+13% +$206K 0.01% 650
2025
Q4 		$768K Buy
+99,724
New +$786K ﹤0.01% 838

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Rafferty Asset Management's CRVS Position: Q2 2026 in Review

Rafferty Asset Management reduced its Corvus Pharmaceuticals (CRVS) stake by 28% in Q2 2026, selling an estimated $432K and leaving 81,494 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #746.

Rafferty Asset Management first reported a position in CRVS in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.65M in Q1 2026. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Rafferty Asset Management held 81,494 shares of Corvus Pharmaceuticals worth $1.22M as of Q2 2026.
  • Rafferty Asset Management sold 31,114 Corvus Pharmaceuticals shares in Q2 2026, an estimated $432K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #746 holding.
  • Rafferty Asset Management first reported a position in Corvus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Rafferty Asset Management's Corvus Pharmaceuticals position peaked at $1.65M in Q1 2026.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.